Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Virios Therapeutics Inc | VIRI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.4509 | 04:17:23 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.4509 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.279 - 2.42 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.4509 | USD |
Virios Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 8.67M | 19.26M | - | 0 | -5.3M | -0.28 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Virios Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VIRI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.4511 | 0.5292 | 0.4401 | 0.4837387 | 164,742 | -0.0002 | -0.04% |
| 1 Month | 0.3624 | 0.6288 | 0.331 | 0.4668173 | 636,715 | 0.0885 | 24.42% |
| 3 Months | 0.385 | 0.6288 | 0.279 | 0.4316805 | 321,990 | 0.0659 | 17.12% |
| 6 Months | 0.7851 | 1.04 | 0.279 | 0.5972253 | 404,102 | -0.3342 | -42.57% |
| 1 Year | 0.652 | 2.42 | 0.279 | 1.01 | 1,005,585 | -0.2011 | -30.84% |
| 3 Years | 5.60 | 9.1109 | 0.218951 | 1.09 | 494,887 | -5.15 | -91.95% |
| 5 Years | 13.76 | 14.39 | 0.218951 | 1.57 | 477,434 | -13.31 | -96.72% |
Virios Therapeutics Description
| Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia. |
